Frontiers in Medicine (Dec 2020)
Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures
- Juliana Gonçalves,
- Juliana Gonçalves,
- Rita L. Sousa,
- Rita L. Sousa,
- Maria J. Jacinto,
- Daniela A. Silva,
- Daniela A. Silva,
- Filipe Paula,
- Filipe Paula,
- Filipe Paula,
- Rute Sousa,
- Rute Sousa,
- Sara Zahedi,
- Sara Zahedi,
- Joana Carvalho,
- Joana Carvalho,
- M. Guadalupe Cabral,
- M. Guadalupe Cabral,
- Manuela Costa,
- Jaime C. Branco,
- Jaime C. Branco,
- Helena Canhão,
- Helena Canhão,
- José D. Alves,
- José D. Alves,
- José D. Alves,
- Ana M. Rodrigues,
- Ana M. Rodrigues,
- Helena Soares,
- Helena Soares
Affiliations
- Juliana Gonçalves
- Human Immunobiology and Pathogenesis Laboratory, Lisbon, Portugal
- Juliana Gonçalves
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- Rita L. Sousa
- Human Immunobiology and Pathogenesis Laboratory, Lisbon, Portugal
- Rita L. Sousa
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- Maria J. Jacinto
- Católica-Lisbon School of Business and Economics, Catholic University of Portugal, Lisbon, Portugal
- Daniela A. Silva
- Human Immunobiology and Pathogenesis Laboratory, Lisbon, Portugal
- Daniela A. Silva
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- Filipe Paula
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- Filipe Paula
- Internal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, Portugal
- Filipe Paula
- Immune Response and Vascular Disease Laboratory, Lisbon, Portugal
- Rute Sousa
- Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal
- Rute Sousa
- EpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, Portugal
- Sara Zahedi
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- Sara Zahedi
- Computational and Experimental Biology Laboratory, Lisbon, Portugal
- Joana Carvalho
- Internal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, Portugal
- Joana Carvalho
- Immune Response and Vascular Disease Laboratory, Lisbon, Portugal
- M. Guadalupe Cabral
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- M. Guadalupe Cabral
- Tissue Repair and Inflammation Laboratory, Lisbon, Portugal
- Manuela Costa
- 0Rheumatology Department, CHLO, Egas Moniz Hospital, Lisbon, Portugal
- Jaime C. Branco
- Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal
- Jaime C. Branco
- 0Rheumatology Department, CHLO, Egas Moniz Hospital, Lisbon, Portugal
- Helena Canhão
- Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal
- Helena Canhão
- EpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, Portugal
- José D. Alves
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- José D. Alves
- Internal Medicine Department IV/Immune Mediated Systemic Diseases (UDIMS), Fernando Fonseca Hospital, Amadora, Portugal
- José D. Alves
- Immune Response and Vascular Disease Laboratory, Lisbon, Portugal
- Ana M. Rodrigues
- Comprehensive Health Research Center (CHRC), NOVA Medical School, Lisbon, Portugal
- Ana M. Rodrigues
- EpiDoC Unit, CEDOC, NOVA Medical School, UNL, Lisbon, Portugal
- Helena Soares
- Human Immunobiology and Pathogenesis Laboratory, Lisbon, Portugal
- Helena Soares
- CEDOC-Chronic Diseases Research Center, NOVA Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon, Lisbon, Portugal
- DOI
- https://doi.org/10.3389/fmed.2020.603996
- Journal volume & issue
-
Vol. 7
Abstract
Seroprevalence studies are crucial both for estimating the prevalence of SARS-CoV-2 exposure and to provide a measure for the efficiency of the confinement measures. Portuguese universities were closed on March 16th 2020, when Portugal only registered 62 SARS-CoV-2 infection cases per million. We have validated a SARS-CoV-2 ELISA assay to a stabilized full-length spike protein using 216 pre-pandemic and 19 molecularly diagnosed SARS-CoV-2 positive individual's samples. At NOVA University of Lisbon, presential work was partially resumed on May 25th with staggered schedules. From June 15th to 30th, 3–4 weeks after the easing of confinement measures, we screened 1,636 collaborators of NOVA university of Lisbon for the presence of SARS-CoV-2 spike specific IgA and IgG antibodies. We found that spike-specific IgG in 50 of 1,636 participants (3.0%), none of which had anti-spike IgA antibodies. As participants self-reported as asymptomatic or paucisymptomatic, our study also provides a measurement of the prevalence of asymptomatic/paucisymptomatic SARS-CoV-2 infections. Our study suggests that essential workers have a 2-fold increase in viral exposure, when compared to non-essential workers that observed confinement. Additional serological surveys in different population subgroups will paint a broader picture of the effect of the confinement measures in the broader community.
Keywords
- SARS-CoV2
- serosurvey
- IgA and IgG
- pauci/asymptomatic COVID-19 prevalence
- post-confinement community setting